Abstract
Background: Colorectal cancer is the second leading cause of cancer-related death in the United States, in part, because one third of Americans fail to get screened. In a prior randomized controlled trial, we found that an iPad patient decision aid called Mobile Patient Technology for Health-CRC (mPATH-CRC) doubled the proportion of patients who completed colorectal cancer screening.
Methods: All data for the current analysis were collected as part of a randomized controlled trial to determine the impact of mPATH-CRC on receipt of colorectal cancer screening within 24 weeks. Participants were enrolled from six community-based primary care practices between June 2014 and May 2016 and randomized to either usual care or mPATH-CRC. Six potential mediators of the intervention effect on screening were considered. The Iacobucci method was used to assess the significance of the mediation.
Results: A total of 408 patients had complete data for all potential mediators. Overall, the potential mediators accounted for approximately three fourths (76.3%) of the effect of the program on screening completion. Perceived benefits, self-efficacy, ability to state a screening decision, and patient–provider discussion were statistically significant mediators. Patient–provider discussion accounted for the largest proportion of the effect of mPATH-CRC (70.7%).
Conclusions: mPATH-CRC increased completion of colorectal cancer screening by affecting patient-level and system-level mediators. However, the most powerful mediator was the occurrence of a patient–provider discussion about screening. Digital interventions like mPATH-CRC are an important adjunct to the patient–provider encounter.
Impact: Understanding the factors that mediated mPATH-CRC's success is paramount to developing other effective interventions.
Introduction
Colorectal cancer is a major health problem throughout the world (1), and it is the second leading cause of cancer-related death in the United States (2). While screening reduces colorectal cancer incidence and mortality, only two-thirds of age-eligible Americans are screened for colorectal cancer (3). The burden of colorectal cancer is even greater in groups prone to health disparities. Past studies have shown that participation in colorectal cancer screening is lower among racial/ethnic minorities, individuals with low health literacy, and individuals with lower socioeconomic status (4, 5).
Understanding the factors that influence a patient's screening decision and subsequent completion of screening is paramount to improving colorectal cancer screening rates. Several qualitative studies have investigated perceptions and experiences with colorectal cancer screening. One meta-analysis examined 94 studies to generate an expanded theory of colorectal cancer screening participation (6). The barriers to colorectal cancer screening included language barriers, logistical challenges, and cultural beliefs. Facilitators of colorectal cancer screening included awareness of colorectal cancer screening, attitudes toward colorectal cancer screening, and motivation for screening (6).
Past studies have looked at different interventions to improve colorectal cancer screening such as decision aids, direct-mailed fecal immunochemical test (FIT), colonoscopy outreach, reminder systems and patient navigation. In our prior randomized controlled trial of a Web-based decision aid, although the intervention increased desire to receive colorectal cancer screening, it did not significantly impact screening test ordering or completion (7). Several small comparative effectiveness trials and pilot studies have shown improved colon cancer screening rates in safety net clinics with direct mailed FIT cards (8). The Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) study was a large scale pragmatic study that evaluated effectiveness of a mailed FIT intervention using electronic health record (EHR) tools delivered by clinic staff at federally qualified health centers (FQHC) patient populations (9). The trial showed a higher adjusted clinic-level proportion of participants who completed a FIT (13.9% in intervention arm vs. 10.4% in the usual care arm; ref. 9). Mailed outreach with colonoscopy invitation has also been tested among vulnerable populations and showed some improvement in screening rates (10). The success of many direct mailed interventions seems to be linked to reminder systems and patient navigation. Many patients fail to return cards based on fear of results, concern for cost of follow up test, unease of mailing fecal matter or forgetfulness (11). Live phone call reminder systems seem to be more effective than written or automated communication (12). Patient navigation has also been found to be an effective adjunct to screening interventions with one study showing intervention patients were more likely to undergo colorectal cancer screening than control patients (33.6% vs. 20.0%; P < 0.001; refs. 13, 14).
In our randomized controlled trial looking at the effect of digital health intervention on colorectal cancer screening in vulnerable patients, we found that patients who used the Mobile Patient Technology for Health-CRC (mPATH-CRC) iPad program were twice as likely to complete screening (15). mPATH-CRC is an iPad application that informs patients of the need for screening, helps them make a decision, lets them “self-order” a test, and sends automated electronic messages to help them complete the test. Patients use mPATH-CRC at their primary care provider's (PCP) office on a device owned by the practice and can receive follow-up support via text messages or emails on their own devices (15). The mPATH-CRC study targeted a population prone to health disparities, with greater than 50% of the population having incomes less than $20,000 and 37% of the population reporting poor to fair health status. Therefore, we wanted to evaluate what factors led to the success of the intervention in this vulnerable patient population and mediated the common known barriers and facilitators of colorectal cancer screening. Mediation analysis allows us to determine the most effective components of the intervention to inform future implementation and scaling.
The key mediators of the intervention can be thought of in three categories: traditional targets of decision aids (knowledge, attitudes, and beliefs), patient provider discussions, and intent to screen in the next 30 days. We examined these mediators as they relate to colorectal cancer screening completion.
Materials and Methods
Design overview
All data for the current analysis was collected as part of a randomized controlled trial to determine the impact of mPATH-CRC on receipt of colorectal cancer screening within 24 weeks. Primary results and details regarding methods have been described previously (15). Briefly, participants were enrolled from six community-based primary care practices between June 2014 and May 2016 and randomized to either usual care or mPATH-CRC. Eligible patients included English-speaking individuals aged 50 to 74 years who were scheduled to see a PCP and were due for colorectal cancer screening. The intervention was administered to patients prior to the visit to provide “just in time” information that patients could discuss with their provider if they had questions. After patients used mPATH the research assistant attached a brief flyer to their clinic paperwork to let the provider know what the patient chose in terms of screening. If the patient was unsure or did not want screening, the flyer encouraged the provider to discuss with the patient. In addition the mPATH program prompted patients who chose not be to be screened with a message that stated “if you have any questions or concerns about getting tested, please talk to your doctor.” Twenty-four weeks after the visit, study staff interviewed patients and reviewed charts to determine whether colorectal cancer screening had been ordered and completed. Study interviewers and outcome assessors were blinded to participant allocation. The Wake Forest University Health Sciences Institutional Review Board approved the study, all participants provided written informed consent, and the study was conducted in accordance with recognized ethical guidelines.
Interventions
Content and usability of the two programs (mPATH-CRC and the Control Program) have been previously published (15, 16). Briefly, the mPATH-CRC intervention had three primary components: (i) a previously validated brief decision aid about colorectal cancer screening reviewing the two most commonly recommended colorectal cancer screening tests, fecal testing for blood and colonoscopy, (ii) patient self-ordering of screening tests which triggered the research assistant to enter a cosignature required order under the PCP's name in the EHR, and (iii) follow-up electronic messages delivered by text or e-mail designed to promote screening test completion. The Control Program consisted of a brief video about diet and exercise that was produced by the Centers for Disease Control.
Measures
Participants viewed mPATH-CRC or the Control Program and completed a post-program survey that captured attitudes and beliefs about screening immediately prior to their regularly scheduled primary care appointment (Fig. 1). Telephone surveys were administered the next business day to determine if the patients discussed screening with their PCPs, and 24 weeks after the screening visit to determine whether screening was ordered and completed. Sociodemographic variables assessed at baseline included age, sex, race, and ethnicity, educational attainment, marital status, health insurance coverage, employment, and income. Health literacy was estimated using the single-item health literacy screening question (“How confident are you filling out medical forms by yourself?”; ref. 17).
Overview of timing of study measures, illustrating how the study design was administered. One week prior to the PCP visit, the patient underwent a phone eligibility survery. At the day of the visit, participants viewed mPATH-CRC or the Control Program and completed a post-program survey that captured attitudes and beliefs about screening immediately prior to their regularly scheduled primary care appointment. Telephone surveys were administered the next business day to determine whether the patients discussed screening with their PCPs, and 24 weeks after the screening visit to determine whether screening was ordered and completed.
Outcome
The primary trial outcome was chart-verified completion of a colorectal cancer screening test within 24 weeks of study enrollment.
Mediators
We assessed six potential mediators across three categories: traditional targets of decision aids (benefits, barriers, self-efficacy, and ability to make a decision), patient–provider discussions, and intent to screen in the next 30 days. Targets of decision aids were measured in the post-program survey. Colorectal cancer screening attitudes and beliefs were assessed with a 5-point Likert-type items modified from a validated instrument (18). Five items addressed the perceived benefits of screening (i.e., ability to detect cancer early, ability to save lives) and five item assessed patients' fears and concerns (i.e., fear of receiving bad news, fear that tests are painful, concerns that tests are embarrassing). We measured self-efficacy to complete colorectal cancer screening with a 1-item validated instrument from Vernon and colleagues (19) Higher scores on these three measures indicate a more positive attitude toward colorectal screening. Ability to make a colorectal cancer screening decision was measured with the ability to state a screening preference item. The intention to receive screening was also measured on the postprogram survey. We assessed ability to state a preference with the single item, “If you were going to be tested for colon cancer, which test would you want to have?”; possible answers included “stool test for blood,” “colonoscopy,” “I never want to be tested,” and “I don't know enough to decide.” Intention to receive screening was measured with the item “Are you seriously thinking about getting tested for colon cancer?” with possible answers ranging from “Yes, within the next 30 days” to “No, I am not thinking of getting tested.” Patient–provider discussion about colorectal screening (yes or no) was assessed during the next day telephone survey using the item “At this visit, did you and your doctor discuss getting tested (or screened) for colon cancer?”
Statistical analysis
Logistic or linear regression was used to assess the effect of the intervention on the potential mediators and to evaluate the association between mediators and colorectal cancer screening completion. The method proposed by Iacobucci (20) was used to assess the significance of each mediator separately. The product of coefficients approach (21) was used to extend Icaobucci's method to allow for multiple mediators. For the multiple mediator model, the SE was calculated using bootstrap. Percent mediation was calculated using the crude estimate of ab/(ab + c') (22).
Results
A total of 450 participants who were between the ages of 50 and 74 and due for colorectal screening were accrued from six community-based primary care clinics in North Carolina between June 2014 and May 2016; 223 were randomized to the mPATH-CRC arm and 227 to the Control arm. Participant characteristics are shown in Table 1. Briefly, 54% were female, 38% self-identified as African American, 63% were unemployed, 53% had annual incomes less than $20,000, and 37% had limited health literacy. As previously published, participants in the mPATH-CRC arm were twice as likely to have colorectal cancer screening compared with participants in the Control arm (30% vs. 15%), with an accompanying difference in test ordering in the arms (69% vs. 32%; ref. 15). The increase in ordering was apparent for both fecal blood tests (36% vs. 11%) and colonoscopies (32% vs. 21%). Overall, patients in both the mPATH and Control arms were equally likely to complete colorectal cancer tests once they were ordered (43% and 46% respectively, P = 0.70); however, participants were more likely to complete an ordered colonoscopy (61%) compared with an ordered fecal test (26%).
Baseline characteristics of mPATH-CRC colorectal cancer screening trial participants.
Mediators of completion of screening
As seen in Table 2, the mPATH-CRC program had a significant effect on all the potential mediators of test completion. Participants randomized to the mPATH-CRC arm were more likely: to state a screening decision, to report intent to have a screening test in the next month, and to report a patient–provider discussion about colorectal screening. In addition, perceived benefits, lack of barrier concern, and self-efficacy scores were higher for the mPATH-CRC participants.
Effect of the mPATH-CRC intervention on hypothesized mediators.
As shown in Table 3, all proposed mediators were significantly associated with CRC test completion in univariate analyses.
Association between mediators and colorectal cancer screening completion within the mPATH-CRC trial (N = 450).
After including all potential mediators in a multivariable model (Table 4), the OR for the effect of the mPATH-CRC program on colorectal cancer screening completion dropped from 2.70 [95% confidence interval (CI): 1.66–4.39] to 1.68 (95% CI: 0.98–2.88). Overall, the potential mediators accounted for approximately three fourths (76.3%) of the effect of the program on screening completion. Perceived benefits, self-efficacy, ability to state a screening decision, and patient–provider discussion were statistically significant mediators. Patient–provider discussion accounted for the largest proportion of the effect of mPATH-CRC (70.7%).
Association between mPATH intervention arm and colorectal cancer screening test completion with and without adjustment for mediators.
Discussion
Previous studies have shown that patients' decision to participate in colorectal cancer screening depends on their views of cancer, attitudes toward colorectal cancer screening modalities, and motivation for screening (6). The mPATH-CRC digital health intervention includes a decision aid that targets these patient-level mediators as well as system changes that target structural barriers. Decision aids, like the one incorporated in mPATH-CRC, have been shown to positively impact patients' decision-making abilities and screening intentions (23, 24). We found a similar effect of mPATH-CRC on these patient-level mediators in our analyses. However, the most powerful mediator of screening completion we observed was the occurrence of a patient–provider discussion about screening.
Other studies have found that a physician's recommendation is one of the most powerful motivators for patients to accept screening (25–27) Patients' trust and value physician guidance on important decisions, especially in vulnerable populations (28, 29). In our randomized controlled trial, half of patients who used mPATH-CRC ordered their own screening test via the program, but 76% reported discussing screening with their provider. This finding illustrates that even patients who order their own screening may value discussing their decision with their provider. By administering mPATH-CRC immediately before a medical visit, the program provides “just in time” information delivery to patients and may prompt patients to engage in screening discussions with their providers. The program also ends with a prompt to ask your provider questions or clarify issues of concern which also helps to foster patient–provider discussion. Whether mPATH-CRC would yield similar effects on screening rates if it were administered separate from a medical visit is unknown.
Our analysis also found that all mediators accounted for approximately three fourths of the effect of mPATH-CRC, which means that a quarter of mPATH-CRC's effect on screening is due to other aspects of the intervention. One key feature of mPATH-CRC is the ability for patients to self-order a screening test. In an earlier trial of a colorectal screening decision aid that did not include the option for patients to order their own screening, we found that only one third of patients who indicated a desire for immediate screening had a screening test ordered by their provider, and there was no significant difference in completion of screening compared with the Control group (7). Healthcare providers identify lack of time as a major barrier to delivering preventive care services, which may explain this significant gap between patients' desire for screening and receipt of screening (30). By allowing patients to self-order tests, mPATH-CRC reduces time barriers and empowers patients to manage their own care.
Other effective strategies for off-loading work from busy clinicians and facilitating care delivery include patient navigation. Reuland and colleagues combined a colorectal cancer screening decision aid with patient navigation and found colorectal cancer screening rates more than doubled (13). While effective, in-person patient navigation is resource-intensive. In contrast, mPATH-CRC functions as a digital health navigator by facilitating test ordering and encouraging test completion via automated patient reminders. Although we found mPATH-CRC doubled screening rates, we also observed that patients completed only half of ordered screening tests suggesting that some patients will need more than digital navigation. Starting with mPATH-CRC and then stepping-up to in-person navigation as needed may yield higher screening rates with less resources than a pure in-person navigation approach.
Our study has limitations. While our study sample represented socioeconomic diversity, it was limited to English speakers and a single health system. We have since developed a Spanish version of the application that is now being implemented in clinics. The barriers and facilitators of screening and how they mediate completion of screening could differ in other subgroups. In addition, the occurrence of patient–provider discussions about colorectal cancer screening was based on patient report, and we did not audiotape encounters to explore the content of those discussions.
In summary, mPATH-CRC increased completion of colorectal cancer screening by affecting traditional targets of decision aids including perceived benefits, self-efficacy, and ability to form a screening decision; however, the most powerful mediator was the occurrence of a patient–provider discussion about screening. The ability of patients to self-order a screening test may also account for a significant proportion of mPATH-CRC's effect. Given the importance of patient–provider discussions, digital interventions like mPATH-CRC are an important adjunct to the patient–doctor encounter to allow for better shared-decision making discussions but are not a replacement. Future research should investigate factors that lead to test completion and strategies for helping patients complete ordered tests. This could consist of a more robust reminder system, live phone calls from clinic staff, and phased in patient navigation.
Disclosure of Potential Conflicts of Interest
D.P. Miller has ownership interest (including patents) in the mPATH app if it leads to a commercial product (there is no commercial product now). No potential conflicts of interest were disclosed by the other authors.
Authors' Contributions
Conception and design: N.M. Denizard-Thompson, D.P. Miller, J.G. Spangler, K.E. Weaver
Development of methodology: D.P. Miller, J.G. Spangler, K.E. Weaver
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.P. Miller, J.G. Spangler
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.P. Miller, A.C. Snavely, L.D. Case, K.E. Weaver
Writing, review, and/or revision of the manuscript: N.M. Denizard-Thompson, D.P. Miller, A.C. Snavely, J.G. Spangler, L.D. Case, K.E. Weaver
Study supervision: D.P. Miller
Acknowledgments
This study received funding from the NCI (R01CA178941). This study was supported by the Wake Forest Clinical and Translational Science Institute study coordinator pool (UL1TR001420) and by the Wake Forest Comprehensive Cancer Center shared resources (CCSG P30CA012197).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Footnotes
Cancer Epidemiol Biomarkers Prev 2020;29:1564–9
- Received September 27, 2019.
- Revision received December 9, 2019.
- Accepted May 4, 2020.
- Published first May 7, 2020.
- ©2020 American Association for Cancer Research.
References
Volume 29, Issue 8
